Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Hadfield

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 18, 2020
A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanomaMatthew J Hadfield, Gracia Mui
Cancer Journal (Sudbury, Mass.)|March 25, 2024
What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?Matthew J Hadfield, Ryan J Sullivan
Journal of Osteopathic Medicine|November 20, 2021
Bursting the bubble: hereditary spherocytosis masking poor glycemic controlAshley Gordon, Deep Pachu, Matthew J Hadfield
Journal of Personalized Medicine|April 25, 2025
Targeted Therapeutic Approaches for the Treatment of Cancer: The Future Is BrightMatthew J Hadfield, Benedito A Carneiro, Liang Cheng
Journal of the American Academy of Dermatology|August 25, 2024
Dermatologic toxicities of antibody-drug conjugatesChristian Gronbeck, Matthew J Hadfield, Jane M Grant-Kels
Melanoma Research|June 27, 2020
Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapiesMatthew J Hadfield, Racquel Helsing, Jane M Grant-Kels
Cureus|September 10, 2019
Case of Anthracycline-induced Cardiogenic Shock: A Call to Optimize Modifiable Cardiac Risk Factors Prior to ChemotherapyAndre Gabriel, Bryan Stringer, Matthew J Hadfield, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 16, 2021
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858RMatthew J Hadfield, Alla Turshudzhyan, Khalid Shalaby, et al.
Cureus|August 15, 2019
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After PembrolizumabShashank Sama, Matthew J Hadfield, Nerea Lopetegui Lia, et al.
The Annals of Pharmacotherapy|February 25, 2023
Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor AntagonistsMatthew J Hadfield, Vikram Lyall, Lisa M Holle, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 18, 2020
A fatal case of Immune thrombocytopenia secondary to the immune checkpoint inhibitor ipilimumab in a patient with BRAF wild type metastatic melanomaMatthew J Hadfield, Gracia Mui
Cancer Journal (Sudbury, Mass.)|March 25, 2024
What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?Matthew J Hadfield, Ryan J Sullivan
Journal of Osteopathic Medicine|November 20, 2021
Bursting the bubble: hereditary spherocytosis masking poor glycemic controlAshley Gordon, Deep Pachu, Matthew J Hadfield
Journal of Personalized Medicine|April 25, 2025
Targeted Therapeutic Approaches for the Treatment of Cancer: The Future Is BrightMatthew J Hadfield, Benedito A Carneiro, Liang Cheng
Journal of the American Academy of Dermatology|August 25, 2024
Dermatologic toxicities of antibody-drug conjugatesChristian Gronbeck, Matthew J Hadfield, Jane M Grant-Kels
Melanoma Research|June 27, 2020
Desmoplastic melanoma: an updated clinical review and the emerging role of genetic markers and immunotherapiesMatthew J Hadfield, Racquel Helsing, Jane M Grant-Kels
Cureus|September 10, 2019
Case of Anthracycline-induced Cardiogenic Shock: A Call to Optimize Modifiable Cardiac Risk Factors Prior to ChemotherapyAndre Gabriel, Bryan Stringer, Matthew J Hadfield, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|November 16, 2021
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858RMatthew J Hadfield, Alla Turshudzhyan, Khalid Shalaby, et al.
Cureus|August 15, 2019
Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After PembrolizumabShashank Sama, Matthew J Hadfield, Nerea Lopetegui Lia, et al.
The Annals of Pharmacotherapy|February 25, 2023
Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor AntagonistsMatthew J Hadfield, Vikram Lyall, Lisa M Holle, et al.
Pageof 4